Ampersand today announces Innovate UK grant win to develop digital therapy solutions for people with Rheumatoid Arthritis
TechForce19 and DigitalHealth.London accelerator company Ampersand Health announces it was selected from over 8600 applications to receive funding by the UK Government to develop digital self-management solutions for shielding RA patients.
About Rheumatoid Arthritis Rheumatoid arthritis is a complex and serious, systemic autoimmune condition where the immune system attacks the joint tissue causing inflammation, stiffness, pain and extreme fatigue. This chronic disease, which chiefly impacts upon joints can also affect other organs such as the heart, eyes and lungs; and when left untreated, can cause serious disability and extra articular complications which can be life limiting. About Ampersand Health Ampersand Health is a social purpose company, founded by doctors and patients to improve the health and happiness of people with long term inflammatory conditions. The company is pioneering the development of behavioural and data-science based digital therapies for people with immune-mediated diseases like Crohn’s, Colitis, Arthritis and Psoriasis. Ampersand Health is recognised in the Digital Health Global 100, and has won the HSJ Award, the NHS Ideas Lab, the NHS Hackfest and competitive grants from government and industry. The company was selected for PWC Scale Health and the NHS’s DigitalHealth. London accelerator. Ampersand Health is also one of the 18 digital innovators currently supporting vulnerable people during the COVID-19 outbreak as part of the TechForce19 challenge. My Arthritis is free for patients and can be downloaded from the AppStore (iOS) and Google Play (Android). Media Links:
- Image link: https://www.ampersandhealth.co.uk/wp-content/uploads/2020/05/MyArthritisxInnovate_Post-2.png
- My Arthritis - App Store download link: https://apps.apple.com/us/app/my-arthritis/id1431862637
- My Arthritis - Google Play download link: https://play.google.com/store/apps/details?id=nhs.ibd.com.rheumatology&hl=en_GB